Across TCGA pan-cancer cohorts, PRAMEF20 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PRAMEF20 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PRAMEF20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and OV are the cancer types where PRAMEF20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
UCEC	DFS	Median	II,III,IV	1.000	0.429	.004	32	view →
OV	DFS	Median	All	0.142	0.541	.002	12	view →
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	12	view →
UVM	DFS	Median	All	0.180	0.744	.019	6	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →
SKCM	DFS	Median	II,III,IV	0.353	0.599	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

Exploration

Same gene, other analysis: PRAMEF20 tumor-vs-normal RNA expression · all PRAMEF20 data types